SmithKline-Beecham's Coreg reduces CHF mortality by 67% in trial -- AHA meeting.
SMITHKLINE BEECHAM COREG (CARVEDILOL) DECREASES MORTALITY BY 67% in patients with mild to severe congestive heart failure, according to data from a multi-center trial presented at the American Heart Association's 68th Scientific Sessions in Anaheim, California Nov. 13. The mortality rate in the carvedilol arm was 3% (21/696) compared to 7.8% (31/398) in placebo. The risk reduction was similar across CHF severity, Packer reported. Risk reduction among Class II patients using carvedilol was 68% (2.4% mortality in carvedilol vs. 5.8% mortality in placebo) while risk reduction in Class III-IV was 67% (3.7% vs. 10%).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth